Cholylhydroxamic Acid | 25873-29-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Cholylhydroxamic Acid
• 英文别名: (4R)-4-[(8R,9S,10S,13R,14S,17R)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-N-hydroxypentanamide
• CAS: 25873-29-4
• 化学式: C₂₄H₄₁NO₂
• 分子量: 375.595
• InChiKey: FMSFPPJYYUSWNC-KBMWBBLPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.2
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-羟基-2-甲基苯甲酰胺 、 胆酸 生成 Cholylhydroxamic Acid
  参考文献：
  名称：

  Bile acid inhibitors of metalloproteinase enzymes

  摘要：

  本发明涉及一种胆酸衍生物，其包括在羧基上与羟肟酸或羟肟酸酯衍生的胆酸。胆酸化合物中的羧基还可以与氨基酸或寡肽衍生物发生衍生，其C-末端与羟肟酸或羟肟酸酯衍生。本发明还涉及一种使用胆酸或胆酸衍生物抑制金属蛋白酶酶的方法，包括将金属蛋白酶与有效量的胆酸或胆酸衍生物接触。在另一实施方式中，本发明进一步涉及使用胆酸或胆酸衍生物治疗一种通过抑制金属蛋白酶酶而得到缓解的疾病的方法。在该方法中，向人类或其他哺乳动物施用治疗有效量的胆酸、胆酸衍生物或其生理上可接受的盐。

  公开号：

  US05646316A1

文献信息

• Modified polysaccharides exhibiting altered biological recognition
  申请人：——

  公开号：US20030236224A1

  公开（公告）日：2003-12-25

  The invention relates to polysaccharides, polysaccharide conjugates and polysaccharide complexes with altered biological properties, methods to produce these polysaccharides, polysaccharide conjugates and polysaccharide complexes and methods to use these conjugates and complexes in the treatment of iron overload or iron deficiency diseases.

  本发明涉及改变生物学性质的多糖、多糖共轭物和多糖复合物，制备这些多糖、多糖共轭物和多糖复合物的方法，以及在治疗铁过载或铁缺乏病时使用这些共轭物和复合物的方法。
• Pharmaceutical combinations for topical use based on iron chelators, metalloprotease inhibitors and factor XIII for the treatment of lipodermatosclerosis and trophic lesions of the cutaneous tissues and muccous membranes
  申请人：ZAMBONI, Paolo

  公开号：EP1364645A1

  公开（公告）日：2003-11-26

  The present invention relates to pharmaceutical combinations based on iron chelators, metalloprotease inhibitors and factor XIII for the topical treatment of lipodermatosclerosis and trophic lesions of the cutaneous tissues and mucous membranes in general, and venous ulcers in particular.

  本发明涉及以铁螯合剂、金属蛋白酶抑制剂和因子 XIII 为基础的药物组合，用于局部治疗脂溢性皮肤硬化症以及皮肤组织和粘膜的营养性病变，尤其是静脉溃疡。
• MODIFIED POLYSACCHARIDES EXHIBITING ALTERED BIOLOGICAL RECOGNITION
  申请人：BIOMEDICAL FRONTIERS, INC.

  公开号：EP1037642B1

  公开（公告）日：2009-03-18
• COMPOSITIONS AND METHODS FOR TREATING OBESITY
  申请人：Atheronova Operations, Inc.

  公开号：EP2485738A2

  公开（公告）日：2012-08-15
• Lipodissolving dermatological topical preparation
  申请人：Zadini Filiberto

  公开号：US20070071706A1

  公开（公告）日：2007-03-29

  A dermatological topical preparation such as a cream, a lotion, an emulsion, a paste, an ointment and the likes where a lipo-dissolving emulsifier such as a biliary compound is transdermally delivered through the superficial layers of the skin into the subcutaneous adipose tissue with the use of skin permeability enhancers. Some of these skin permeability enhancers are cyclodextrins, while others are substances which have the peculiar property of enhancing delivery of the lipo-dissolving substance locally into the adipose subcutaneous tissue maximizing subcutaneous uptake while minimizing systemic absorption in order to achieve maximization of local effect.